Clinical Trial Update: Tocilizumab for Acute Chest Syndrome [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating Tocilizumab for Acute Chest Syndrome in patients with sickle cell disease; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chest Syndrome
• Sickle Cell Disease

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: University of Chicago | Conditions: Sickle Cell Disease, Acute Chest Syndrome | Phase 2 | Status: RECRUITING